Pathogenesis of vestibular schwannoma in ring chromosome 22
© Denayer et al; licensee BioMed Central Ltd. 2009
Received: 15 January 2009
Accepted: 22 September 2009
Published: 22 September 2009
Ring chromosome 22 is a rare human constitutional cytogenetic abnormality. Clinical features of neurofibromatosis type 1 and 2 as well as different tumour types have been reported in patients with ring chromosome 22. The pathogenesis of these tumours is not always clear yet.
We report on a female patient with a ring chromosome 22 presenting with severe mental retardation, autistic behaviour, café-au-lait macules and facial dysmorphism. Peripheral blood lymphocytes were karyotyped and array CGH was performed on extracted DNA. At the age of 20 years she was diagnosed with a unilateral vestibular schwannoma. Tumour cells were analyzed by karyotyping, array CGH and NF2 mutation analysis.
Karyotype on peripheral blood lymphocytes revealed a ring chromosome 22 in all analyzed cells. A 1 Mb array CGH experiment on peripheral blood DNA showed a deletion of 5 terminal clones on the long arm of chromosome 22. Genetic analysis of vestibular schwannoma tissue revealed loss of the ring chromosome 22 and a somatic second hit in the NF2 gene on the remaining chromosome 22.
We conclude that tumours can arise by the combination of loss of the ring chromosome and a pathogenic NF2 mutation on the remaining chromosome 22 in patients with ring chromosome 22. Our findings indicate that patients with a ring 22 should be monitored for NF2-related tumours starting in adolescence.
Ring chromosome 22 [r(22)] is a rare human constitutional abnormality. A distinct characteristic phenotype has not been delineated, but frequently reported features are delayed motor development, severe speech disability, hypotonia and microcephaly. In addition growth retardation, ataxia and seizures or abnormal EEG can be observed. Dysmorphic features are variable and mostly mild. Epicanthal folds, full eyebrows and large ears have been reported most frequently [1–4]. Aggressive behaviour as well as autistic disorder and hyperactivity are relatively common [1, 3, 4]. Internal organ involvement is rather rare, except for central nervous system malformations . The variable clinical presentation in carriers of a r(22) has been attributed to variable breakpoints and dynamic mosaicism. In common with other ring chromosomes, r(22) is assumed to arise from breakage and subsequent fusion of both chromosome arms with concomitant loss of sequences distal to the breakpoints . Whereas deletion of ribosomal sequences on 22p is unlikely to be of clinical significance, loss of critical genes on 22q as well as unmasking of recessive alleles by the deletion may be expected to contribute to the phenotype. In a large review of 35 reported cases 22q loss varied from less than 69 kb up to 10.2 Mb in size with a weak correlation between the phenotypic variables and deletion size . The phenotype can further be affected by the continuously evolving mosaicism (dynamic mosaicism) that is caused by the mitotic instability of the ring chromosome. Sister chromatid exchanges during mitosis can lead to formation of dicentric or interlocked rings and subsequent aneuploidy or rearrangements within the chromosome .
Clinical features compatible with neurofibromatosis type 1 (NF1) and 2 (NF2) have been associated with r(22) [7–12]. Reported features included hearing loss, mental retardation, seizures, meningiomas, peripheral neurofibromas, peripheral schwannomas, spinal tumours and vestibular schwannomas. In most reported cases the tumoural phenotype is most suggestive of NF2. We report on a patient with a r(22) and signs of neurofibromatosis who presented with a unilateral vestibular schwannoma at the age of 20. In DNA extracted from peripheral blood lymphocytes the 22q deletion size was examined by array CGH analysis. Analysis of tumour tissue showed loss of the ring 22 and in addition a pathogenic NF2 mutation.
Cytogenetic analysis of G-banded metaphase chromosomes was performed according to standard cytogenetic procedures on peripheral blood lymphocytes, skin-biopsy derived fibroblasts and on a primary culture of Schwann cells from the vestibular schwannoma. Culture conditions for Schwann cells were as described by Rosenbaum et al.  and Serra et al. .
Fluorescent In Situ Hybridisation (FISH) studies were performed on skin-biopsy derived fibroblasts using probes for NF1 (cFF13 and cFB5D) .
Genomic DNA was extracted from lymphocytes and vestibular schwannoma using standard techniques. Array CGH at 1 Mb resolution was carried out as described previously . In the first array CGH experiment genomic DNA of the proband was used versus female reference DNA, in the second experiment DNA from the vestibular schwannoma of the proband was used versus genomic blood DNA of the proband.
NF1 mutation analysis was conducted as described previously . Briefly cDNA was generated from mRNA and used to amplify the NF1 coding region from position 48 to 8464 in eight overlapping PCR reactions. Each PCR fragment was sequenced using a solid-phase sequencing protocol.
To identify mutations in the NF2 gene Meta-PCR amplification followed by direct sequence analysis of the whole coding sequence including the immediate splice donor and splice acceptor sites was performed. In addition the P044 NF2 multiplex ligation-dependent probe amplification (MLPA) kit (MRC Holland) which measures copy number of all 17 exons of the NF2 gene and promoter was used to identify deletions and duplications of the gene. Loss of heterozygosity (LOH) analysis was carried out using microsattelite markers NF2CA3 (located within intron 1 of the NF2 gene) and D22S268 (located 5 kB telomeric to NF2).
Written informed consent was obtained from the patients parents for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Peripheral blood lymphocyte DNA
Five clones (CTA-299D3, RP5-925J7, CTA-722E9, CTA-799F10, CTB-99K24) were deleted in the telomeric region of chromosome 22q: del 22(q13.32 → qter), comprising a region of approximately 2,5 Mb in size (47,248,304-49,453,810; Ensembl database, Release 52) (Figure 4b-e). This region also comprises the SHANK3/PROSAP2 gene, which has been proposed as a candidate gene for the abnormal brain development and autistic features in patients with r(22) or 22q deletion syndrome [17, 18].
Sequencing of the NF1 gene did not show any pathogenic mutations. NF2 mutation analysis was performed on DNA from both peripheral blood and the vestibular schwannoma. There were no NF2 sequence abnormalities, intragenic deletions or copy number variations in blood. In the tumour DNA an NF2 point mutation was identified in a highly conserved nucleotide within the intron 14 splice donor site (c.1122+2T>A). MLPA and LOH analysis with two NF2 linked microsatellite markers (D22S268 and NF2CA3) showed loss of one copy of the NF2 gene in the vestibular schwannoma. This reflects the loss of the r(22) in the tumour tissue as seen by karyotyping and array CGH.
This is the first report describing the complete pathogenic sequence of tumour formation in a patient with r(22) with loss of the ring chromosome in the tumour tissue and a second hit in the NF2 gene on the remaining chromosome 22.
The karyotype and array CGH showed that the ring chromosome 22 was lost in the vestibular schwannoma. In addition NF2 mutation analysis on the tumour tissue showed a somatic splice-site mutation on the remaining chromosome 22. Predisposition for vestibular schwannomas in carriers of r(22) can be explained by Knudson's two-hit model. Due to the mitotic instability the ring chromosome is prone to loss during somatic mitosis (first hit). A mutation at the NF2 gene on the remaining chromosome 22 (second hit) in cells that have become monosomic for this chromosome can result in tumour development. This mechanism was also suspected by Tsilchorozidou in a patient with r(22) presenting with multiple meningiomas and a unilateral vestibular schwannoma. They found two truncating mutations in meningioma tissue as well as loss of one copy of the NF2 gene by LOH analysis . However they did not prove loss of the ring chromosome in the tumour tissue. Interestingly increased tumour development has also been observed in carriers of other constitutional ring chromosomes, i.e. r(11) and r(13). Moreover the types of malignancy reported in these patients are concordant with the chromosomal assignment of tumour suppressor loci associated with Wilms' tumour (chromosome 11) and retinoblastoma (chromosome 13).
INI1 is a tumour suppressor gene located on chromosome 22 centromeric to NF2. It is involved in the development of malignant rhabdoid tumours and germline INI1 mutations are present in some cases of familial schwannomatosis, a condition characterized by the development of multiple spinal, peripheral and cranial-nerve schwannomas in the absence of vestibular schwannomas . It is possible that still other tumour suppressor genes are located on chromosome 22 . Moreover the CHEK2 gene, which encodes a checkpoint kinase important for the cell's response to DNA damage, has been recognized as a multi-organ cancer susceptibility gene and is located on chromosome 22 about 1 Mb centromeric to NF2. Thus a second hit in these alternative tumour suppressor genes in r(22) carriers that already have lost the ring in a number of cells can result in other tumour types than those typically seen in NF2. Indeed there have been reports of r(22) carriers with development of multiple meningiomas, cutaneous tumours and one testicular tumour but without the typical bilateral vestibular schwannomas of NF2 [8, 11, 12].
The patient reported here had been initially followed with a clinical diagnosis of NF1 because of multiple café-au-lait macules, freckling, a mildly enlarged right optic nerve and several subcutaneous nodules resembling neurofibromas. However these clinical features do not point to a true NF1 phenotype. Skin pigmentation abnormalities have been reported in patients with r(22) [21, 22] and café-au-lait macules have been associated with multiple ring chromosomes (7, 11, 12, 15, 17) [23–27]. In view of the r(22) abnormality we believe that the enlargement of the right optic nerve could be due to a meningioma rather than to an optic glioma.
We conclude that tumours can arise by the combination of loss of the ring chromosome and a pathogenic NF2 mutation on the remaining chromosome 22 in patients with r(22). Our findings indicate that patients with a ring 22 should be monitored for NF2-related tumours starting in adolescence.
ED is predoctoral researcher of the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen. HB is supported by the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen). This work is also supported by research grants from the Fonds voor Wetenschappelijk Onderzoek Vlaanderen (G.0578.06 and G.O551.08 to EL); the Interuniversity Attraction Poles (IAP) granted by the Federal Office for Scientific, Technical and Cultural Affairs, Belgium (2007-2011; P6/05) (EL) and by a Concerted Action Grant from the K.U.Leuven (EL). The authors would like to thank Ine Heyns, Rina Wu and Belinda Carleer for technical assistance. We also acknowledge the support of the NIHR biomedical Research Centre at Central Manchester Universities Foundation Trust.
- De Mas P, Chassaing N, Chaix Y, Vincent MC, Julia S, Bourrouillou G, Calvas P, Bieth E: Molecular Characterisation of a Ring Chromosome 22 in a Patient With Severe Language Delay: a Contribution to the Refinement of the Subtelomeric 22q Deletion Syndrome. J Med Genet. 2002, 39: e17-10.1136/jmg.39.4.e17.View ArticlePubMedPubMed CentralGoogle Scholar
- Ishmael HA, Cataldi D, Begleiter ML, Pasztor LM, Dasouki MJ, Butler MG: Five New Subjects With Ring Chromosome 22. Clin Genet. 2003, 63: 410-414. 10.1034/j.1399-0004.2003.00064.x.View ArticlePubMedGoogle Scholar
- Jeffries AR, Curran S, Elmslie F, Sharma A, Wenger S, Hummel M, Powell J: Molecular and Phenotypic Characterization of Ring Chromosome 22. Am J Med Genet A. 2005, 137: 139-147.View ArticlePubMedGoogle Scholar
- MacLean JE, Teshima IE, Szatmari P, Nowaczyk MJ: Ring Chromosome 22 and Autism: Report and Review. Am J Med Genet. 2000, 90: 382-385. 10.1002/(SICI)1096-8628(20000228)90:5<382::AID-AJMG7>3.0.CO;2-T.View ArticlePubMedGoogle Scholar
- Lejeune J: [On the Duplication of Circular Structures]. Ann Genet. 1968, 11: 71-77.PubMedGoogle Scholar
- Tommerup N, Lothe R: Constitutional Ring Chromosomes and Tumour Suppressor Genes. J Med Genet. 1992, 29: 879-882. 10.1136/jmg.29.12.879.View ArticlePubMedPubMed CentralGoogle Scholar
- Arinami T, Kondo I, Hamaguchi H, Nakajima S: Multifocal Meningiomas in a Patient With a Constitutional Ring Chromosome 22. J Med Genet. 1986, 23: 178-180. 10.1136/jmg.23.2.178.View ArticlePubMedPubMed CentralGoogle Scholar
- Duncan AM, Partington MW, Soudek D: Neurofibromatosis in a Man With a Ring 22: in Situ Hybridization Studies. Cancer Genet Cytogenet. 1987, 25: 169-174. 10.1016/0165-4608(87)90173-7.View ArticlePubMedGoogle Scholar
- Kehrer-Sawatzki H, Udart M, Krone W, Baden R, Fahsold R, Thomas G, Schmucker B, Assum G: Mutational Analysis and Expression Studies of the Neurofibromatosis Type 2 (NF2) Gene in a Patient With a Ring Chromosome 22 and NF2. Hum Genet. 1997, 100: 67-74. 10.1007/s004390050467.View ArticlePubMedGoogle Scholar
- Petrella R, Levine S, Wilmot PL, Ashar KD, Casamassima AC, Shapiro LR: Multiple Meningiomas in a Patient With Constitutional Ring Chromosome 22. Am J Med Genet. 1993, 47: 184-186. 10.1002/ajmg.1320470211.View ArticlePubMedGoogle Scholar
- Tommerup N, Warburg M, Gieselmann V, Hansen BR, Koch J, Petersen GB: Ring Chromosome 22 and Neurofibromatosis. Clin Genet. 1992, 42: 171-177.View ArticlePubMedGoogle Scholar
- Tsilchorozidou T, Menko FH, Lalloo F, Kidd A, De Silva R, Thomas H, Smith P, Malcolmson A, Dore J, Madan K, Brown A, Yovos JG, Tsaligopoulos M, Vogiatzis N, Baser ME, Wallace AJ, Evans DG: Constitutional Rearrangements of Chromosome 22 As a Cause of Neurofibromatosis 2. J Med Genet. 2004, 41: 529-534. 10.1136/jmg.2003.016774.View ArticlePubMedPubMed CentralGoogle Scholar
- Rosenbaum T, Rosenbaum C, Winner U, Muller HW, Lenard HG, Hanemann CO: Long-Term Culture and Characterization of Human Neurofibroma-Derived Schwann Cells. J Neurosci Res. 2000, 61: 524-532. 10.1002/1097-4547(20000901)61:5<524::AID-JNR7>3.0.CO;2-Z.View ArticlePubMedGoogle Scholar
- Serra E, Rosenbaum T, Winner U, Aledo R, Ars E, Estivill X, Lenard HG, Lazaro C: Schwann Cells Harbor the Somatic NF1 Mutation in Neurofibromas: Evidence of Two Different Schwann Cell Subpopulations. Hum Mol Genet. 2000, 9: 3055-3064. 10.1093/hmg/9.20.3055.View ArticlePubMedGoogle Scholar
- Wu R, Legius E, Robberecht W, Dumoulin M, Cassiman JJ, Fryns JP: Neurofibromatosis Type I Gene Mutation in a Patient With Features of LEOPARD Syndrome. Hum Mutat. 1996, 8: 51-56. 10.1002/(SICI)1098-1004(1996)8:1<51::AID-HUMU7>3.0.CO;2-S.View ArticlePubMedGoogle Scholar
- Menten B, Maas N, Thienpont B, Buysse K, Vandesompele J, Melotte C, de Ravel T, Van Vooren S, Balikova I, Backx L, Janssens S, De Paepe A, De Moor B, Moreau Y, Marynen P, Fryns JP, Mortier G, Devriendt K, Speleman F, Vermeesch JR: Emerging Patterns of Cryptic Chromosomal Imbalance in Patients With Idiopathic Mental Retardation and Multiple Congenital Anomalies: a New Series of 140 Patients and Review of Published Reports. J Med Genet. 2006, 43: 625-633. 10.1136/jmg.2005.039453.View ArticlePubMedPubMed CentralGoogle Scholar
- Bonaglia MC, Giorda R, Borgatti R, Felisari G, Gagliardi C, Selicorni A, Zuffardi O: Disruption of the ProSAP2 Gene in a T(12;22)(Q24.1;Q13.3) Is Associated With the 22q13.3 Deletion Syndrome. Am J Hum Genet. 2001, 69: 261-268. 10.1086/321293.View ArticlePubMedPubMed CentralGoogle Scholar
- Wilson HL, Wong AC, Shaw SR, Tse WY, Stapleton GA, Phelan MC, Hu S, Marshall J, McDermid HE: Molecular Characterisation of the 22q13 Deletion Syndrome Supports the Role of Haploinsufficiency of SHANK3/PROSAP2 in the Major Neurological Symptoms. J Med Genet. 2003, 40: 575-584. 10.1136/jmg.40.8.575.View ArticlePubMedPubMed CentralGoogle Scholar
- Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P: Germline Mutation of INI1/SMARCB1 in Familial Schwannomatosis. Am J Hum Genet. 2007, 80: 805-810. 10.1086/513207.View ArticlePubMedPubMed CentralGoogle Scholar
- Lekanne Deprez RH, Groen NA, van Biezen NA, Hagemeijer A, van Drunen E, Koper JW, Avezaat CJ, Bootsma D, Zwarthoff EC: A T(4;22) in a Meningioma Points to the Localization of a Putative Tumor-Suppressor Gene. Am J Hum Genet. 1991, 48: 783-790.PubMedPubMed CentralGoogle Scholar
- Ritter CL, Steele MW, Wenger SL, Cohen BA: Chromosome Mosaicism in Hypomelanosis of Ito. Am J Med Genet. 1990, 35: 14-17. 10.1002/ajmg.1320350104.View ArticlePubMedGoogle Scholar
- Woods CG, Bankier A, Curry J, Sheffield LJ, Slaney SF, Smith K, Voullaire L, Wellesley D: Asymmetry and Skin Pigmentary Anomalies in Chromosome Mosaicism. J Med Genet. 1994, 31: 694-701. 10.1136/jmg.31.9.694.View ArticlePubMedPubMed CentralGoogle Scholar
- Fagan K, Suthers GK, Hardacre G: Ring Chromosome 11 and Cafe-Au-Lait Spots. Am J Med Genet. 1988, 30: 911-916. 10.1002/ajmg.1320300406.View ArticlePubMedGoogle Scholar
- Morava E, Bartsch O, Czako M, Frensel A, Karteszi J, Kosztolanyi GY: A Girl With Cutaneous Hyperpigmentation, Cafe Au Lait Spots and Ring Chromosome 15 Without Significant Deletion. Genet Couns. 2003, 14: 337-342.PubMedGoogle Scholar
- Shashi V, White JR, Pettenati MJ, Root SK, Bell WL: Ring Chromosome 17: Phenotype Variation by Deletion Size. Clin Genet. 2003, 64: 361-365. 10.1034/j.1399-0004.2003.00146.x.View ArticlePubMedGoogle Scholar
- Wahlstrom J, Bjarnason R, Rosdahl I, Albertsson-Wikland K: Boy With a Ring 7 Chromosome: a Case Report With Special Reference to Dermatological Findings. Acta Paediatr. 1996, 85: 1256-1260.View ArticlePubMedGoogle Scholar
- Zen PR, Pinto LL, Graziadio C, Pereira VB, Paskulin GA: Association of Microcephaly and Cafe-Au-Lait Spots in a Patient With Ring Chromosome 12 Syndrome. Clin Dysmorphol. 2005, 14: 141-143. 10.1097/00019605-200507000-00007.View ArticlePubMedGoogle Scholar
- Vermeesch JR, Melotte C, Froyen G, Van Vooren S, Dutta B, Maas N, Vermeulen S, Menten B, Speleman F, De Moor B, Van Hummelen P, Marynen P, Fryns JP, Devriendt K: Molecular Karyotyping: Array CGH Quality Criteria for Constitutional Genetic Diagnosis. J Histochem Cytochem. 2005, 53: 413-422. 10.1369/jhc.4A6436.2005.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/10/97/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.